Twenty-six million Americans now have type 2 diabetes and nearly 79 million more have pre-diabetes. Genetic defects play a role in causing type 2 diabetes, but for almost all patients these defects have been unknown.
The UCSF Diabetes Family Fund Spring 2011 Call for Proposals is here. The UCSF Diabetes Family Fund for Innovative Patient Care, Education and Scientific Discovery Fund seeks to stimulate and support creative, collaborative and imaginative innovations in diabetes clinical care, patient education, medical training, and diabetes-related clinical and basic research.
Former Center Director, Jeffrey Bluestone, PhD, continues to stay busy in his current position as UCSF Executive Vice Chancellor and Provost. He is helping to tackle the university’s financial crisis while continuing to maintain in the Diabetes Center. Recently, Dr. Bluestone and his fellow leaders announced that UCSF serves as an economic engine for the Bay Area, driving $6.2 billion in industry output and creating more than 39,100 jobs regionwide.
It is truly an honor to lead the Diabetes Center, not only because of the strength of our diabetes research, clinical care and education programs, but because I have the pleasure of working with some of the world’s most accomplished and dedicated diabetes research and medical professionals, collectively focused on improving the lives of those impacted by diabetes.
Suneil Koliwad, MD, of the Gladstone Institute of Cardiovascular Disease has joined the faculty of the UCSF Diabetes Center to continue his research involving inflammation and the role it plays in diabetes. Dr. Koliwad, a practicing endocrinologist, is an expert in understanding how the cellular balance of fat cells - called adipocytes, and macrophages - the body’s scavengers of dead cells, contributes to the development of inflammation in chronic obesity.
Robert Rushakoff, MD, Mary Sullivan, RN, DNP, ANP-BC, CDE, and other UCSF clinicians are focused on improving diabetes management for both hospitalized patients and patients transitioning both into the hospital and then back to their homes. In a recent journal article, Dr. Rushakoff and his colleagues reported how an online educational module completed by 283 pediatric nurses helped to reduce the hospital's insulin error rate from nearly 15% to less than 2%.
Significant progress has been made in improving the results and clinical applicability of pancreatic islet transplantation as a treatment for type 1 diabetes. UCSF is a member of the Clinical Islet Transplant (CIT) Consortium, an international collaborative effort that is conducting several multicenter trials examining the outcomes of pancreatic islet transplantation in patients with type 1 diabetes.
For many, the Thanksgiving holiday is one of good food, family and friends, and a few days off. In my family, we make sure we stop to reflect on all for which we are thankful. For me, I am grateful for the opportunity to lead an outstanding team of researchers and medical professionals who are all committed to discovering better treatments and, ultimately, a cure for diabetes.
The unique program of the UCSF Diabetes Teaching Center brings together the skills of physicians, nurses, pharmacists and nutritionists to provide individuals with therapies, diabetes education and continuing resources. Thousands of people from around the world have completed workshops at the UCSF Diabetes Teaching Center.
Researchers from the UCSF Center for Vulnerable Populations (CVP) at San Francisco General Hospital continue to impact diabetes prevention and management efforts in countless ways through their important translational research.
A number of new investigational studies in diabetes are being launched by the UCSF Pediatric Diabetes Clinical Research Program under the leadership of Steve Gitelman, MD. Investigational studies are studies that are not approved for use in diabetes by the U.S. Food and Drug Administration.
We are honored that ten outstanding diabetes medical professionals and researchers from UCSF, Harvard Medical School, Harvard School of Public Health, Columbia University School of Medicine, and the San Raffaele Hospital and Scientific Institute, Milan Italy will be making presentations at this day-long symposium, moderated by Center Director Matthias Hebrok, PhD.
Even though the Diabetes Center has already received significant funding from the California Institute of Regenerative Medicine (CIRM) for our stem cell research, it was exciting that our expertise in immune tolerance research was recognized and supported through two awards approved by CIRM’s Governing Board on June 22nd.